Document is current
Any future updates will be listed below
-
Authors
Kim, Daniel W.
Lee, Grace
Hong, Theodore S.
Li, Guichao
Horick, Nora K.
Roeland, Eric
Keane, Florence K.
Eyler, Christine
Drapek, Lorraine C.
Ryan, David P.
Allen, Jill N.
Berger, David
Parikh, Aparna R.
Mullen, John T.
Klempner, Sam J.
Clark, Jeffrey W.
Wo, Jennifer Y.
- License Information
-
More Information
Article History
Received: 22 April 2021
Accepted: 1 August 2021
First Online: 3 September 2021
Disclosures
: Theodore S. Hong has served as a compensated consultant for Merck, Novocure, and Synthetic Biologics and serves as research support for Ipsen, BMS, Astra-Zeneca, Taiho, IntraOp, and Tesaro (GlaxoSmithKline). Sam J. Klempner has served as a compensated consultant for Merck, BMS, Eli Lilly, Natera, Astellas, Daiichi Sankyo, and Pieris Oncology and owns stock/equity in Turning Point Therapeutics, Inc. Aparna R. Parikh has received personal fees from Checkmate Pharma, Eli Lilly, Pfizer, Roche, C2I genomics, Research to Institution Puretech, PMV Pharma, Plexxicon, Takeda, BMS, and Novartis. David P. Ryan owns equity in Exact Sciences and Acworth Pharmaceuticals, has grant in SU2C, and serves as a publisher for Uptodate.
